University of Texas/Texas AM Investment Management Co (UTIMCO)’s Viridian Therapeutics VRDN Stock Holding History

University of Texas/Texas AM Investment Management Co (UTIMCO)’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-7,031	Closed	-$965K	–	84
2017 Q3	$965K	Hold	7,031	–	–	2.31%	11
2017 Q2	$1.36M	Hold	7,031	–	–	4.05%	9
2017 Q1	$1.31M	Buy	+7,031	New	+$1.21M	3.43%	11

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return

University of Texas/Texas AM Investment Management Co (UTIMCO)'s VRDN Position: Q4 2017 in Review

University of Texas/Texas AM Investment Management Co (UTIMCO) sold out of Viridian Therapeutics (VRDN) in Q4 2017, closing a stake of 7,031 shares — an estimated $965K sold.

University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in VRDN in Q1 2017 and held it in 3 quarters. The position peaked at $1.36M in Q2 2017. 51 funds tracked by Wall St. Rank hold VRDN as of Q4 2017.

University of Texas/Texas AM Investment Management Co (UTIMCO) reported no remaining Viridian Therapeutics position as of Q4 2017 after selling out during the quarter.
University of Texas/Texas AM Investment Management Co (UTIMCO) sold 7,031 Viridian Therapeutics shares in Q4 2017, an estimated $965K.
University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in Viridian Therapeutics in Q1 2017 and held it in 3 quarters.
University of Texas/Texas AM Investment Management Co (UTIMCO)'s Viridian Therapeutics position peaked at $1.36M in Q2 2017.
51 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2017.

Based on University of Texas/Texas AM Investment Management Co (UTIMCO)'s 13F filing for Q4 2017, filed 8 Feb 2018.